ePrints

Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions

Lookup NU author(s): Professor Moein MoghimiORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2017 Elsevier Ltd. Injection/infusion reactions to nanopharmaceuticals (and particulate drug carriers) are idiosyncratic and well documented. The molecular basis of nanoparticle-mediated injection reactions is debatable, with two hypotheses as front-runners. The first is complement-activation-related 'pseudoallergy', where a causal role for nanoparticle-mediated complement activation in injection/infusion reactions is considered. However, the second hypothesis (the rapid phagocytic response hypothesis) states a transitional link from robust clearance of nanoparticles (NPs) from the blood by strategically placed responsive macrophages to adverse hemodynamic and cardiopulmonary reactions, regardless of complement activation. Here, I critically examine and discuss these hypotheses. Current experimentally derived evidence appears to be more in support of the rapid phagocytic response hypothesis than of the pseudoallergy hypothesis.

Publication metadata

Author(s): Moghimi SM

Publication type: Article

Publication status: Published

Journal: Drug Discovery Today

Year: 2018

Volume: 23

Issue: 5

Pages: 1034-1042

Print publication date: 01/05/2018

Online publication date: 13/11/2017

Acceptance date: 02/04/2016

ISSN (print): 1359-6446

ISSN (electronic): 1878-5832

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.drudis.2017.11.006

DOI: 10.1016/j.drudis.2017.11.006

Altmetrics

Share